The
worldwide skin ulcer treatment market has risen during the last 10-15 years at
much higher rate than initially predicted. This can be attributed partly to the increase
in chronic wounds, but also to the increased costs of the advanced wound care (AWC) medicaments. Depending on the severity of the
complications, the estimated cost of treating diabetic foot ulcers ranged from
$3,959 to $188,645 per patient in the USA in 2011 and the annual wound care
product market was estimated to be over $15bn. In a recent report [Visiongain 2012], the AWC market was estimated to
have reached sales of $2.9bn in the US and $6.6bn world-wide in 2011; with the
global market predicted to reach $16.3bn by 2023.
Current
treatments for non-healing wounds are largely ineffective and expensive. It is
estimated that a new effective product could reap over $1 billion world-wide in
annual sales when approved [Reuters 2011]. The societal benefits of
such a treatment are immeasurable.
The solution
proposed by TRT is based on the unique
characteristics of MSF bioactives, including the parental protein (MSF) and its
synthetic mimetics. TRT's lead
compound, TRT-8174, offers a number of
clinical and commercial competitive advantages over currently available
treatments for chronic ulcers.
TRT is actively looking for early stage investors
References
Reuters (2011). http://www.reuters.com/article/2011/09/14/us-dermasciences-idUSTRE78D6WK20110914
Visiongain (2012). Advanced Wound
Care: World Market Prospects 2013-2023 http://www.marketresearch.com/Visiongain-v1531/Advanced-Wound-Care-Prospects-7366013/
return to home page
|
